Holocene Advisors
PTGX icon

Holocene Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Holocene Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Sell
8,495
-201,421
-96% -$21M ﹤0.01% 671
2026
Q1 		$22.1M Sell
209,916
-103
-0% -$9.12K 0.05% 260
2025
Q4 		$18.3M Buy
+210,019
New +$17.2M 0.04% 291
2025
Q3 		– Sell
-530,326
Closed -$29.3M – 885
2025
Q2 		$29.3M Buy
+530,326
New +$25.5M 0.07% 215
2023
Q3 		– Sell
-802,531
Closed -$22.2M – 851
2023
Q2 		$22.2M Buy
+802,531
New +$20.1M 0.09% 203

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Holocene Advisors's PTGX Position: Q2 2026 in Review

Holocene Advisors reduced its Protagonist Therapeutics (PTGX) stake by 96% in Q2 2026, selling an estimated $21M and leaving 8,495 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #671.

Holocene Advisors first reported a position in PTGX in Q2 2023 and has held it in 5 quarters since. The position peaked at $29.3M in Q2 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Holocene Advisors held 8,495 shares of Protagonist Therapeutics worth $1.04M as of Q2 2026.
  • Holocene Advisors sold 201,421 Protagonist Therapeutics shares in Q2 2026, an estimated $21M.
  • Protagonist Therapeutics made up ﹤0.01% of Holocene Advisors's portfolio in Q2 2026, its #671 holding.
  • Holocene Advisors first reported a position in Protagonist Therapeutics in Q2 2023 and has held it in 5 quarters since.
  • Holocene Advisors's Protagonist Therapeutics position peaked at $29.3M in Q2 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.